代谢功能障碍相关脂肪性肝病合并原发性胆汁性胆管炎的中西医临床研究进展
Clinical Research Progress on Metabolic Dysfunction-Associated Steatotic Liver Disease Combined with Primary Biliary Cholangitis: Insights from Western and Traditional Chinese Medicine
摘要: 代谢功能障碍相关脂肪性肝病(metabolic dysfunction-associated steatotic liver disease, MASLD)是全球范围内发病率最高的慢性肝病之一,其病理过程与肥胖、胰岛素抵抗及代谢综合征密切相关。原发性胆汁性胆管炎(primary biliary cholangitis, PBC)是一种以小胆管破坏和胆汁淤积为特征的自身免疫性肝病,近年来合并MASLD的病例逐渐增多,提示两者在病理机制上可能存在交叉与耦合。二者共病不仅加速肝纤维化进展,还显著增加肝硬化与终末期肝病风险,严重威胁患者健康。现代医学研究认为,该类复合病理状态主要涉及代谢异常、免疫炎症反应、肠–肝轴失衡及昼夜节律与表观遗传学改变等多因素协同作用;中医学则从肝、脾、肾功能失调出发,提出肝郁脾虚证、肝胆湿热证及肝肾阴虚证等核心病机,揭示了痰湿、湿热与阴虚贯穿疾病始终的演变规律。本文将从中西医两个角度对MASLD合并PBC的病因病机进行综述,为进一步开展临床与基础研究提供理论依据。
Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, and its development is closely linked to obesity, insulin resistance, and metabolic syndrome. Primary biliary cholangitis (PBC), an autoimmune liver disease characterized by progressive bile duct injury and cholestasis, has increasingly been reported in patients with MASLD, suggesting shared and interacting mechanisms. The coexistence of these conditions accelerates hepatic fibrosis and markedly increases the risk of cirrhosis and end-stage liver disease, thereby threatening patient health. Modern medical research indicates that this combined pathophysiology involves metabolic disturbances, immune-inflammatory activation, gut-liver axis imbalance, and alterations in circadian rhythm and epigenetic regulation. From the perspective of traditional Chinese medicine (TCM), dysfunction of the liver, spleen, and kidney constitutes the fundamental pathogenesis, with core syndromes including liver qi stagnation with spleen deficiency, damp-heat accumulation in the liver and gallbladder, and liver-kidney yin deficiency. These patterns underscore the continuous involvement of phlegm-dampness, damp-heat, and yin deficiency in disease progression. This review synthesizes recent evidence from both Western medicine and TCM to elucidate the mechanisms of MASLD complicated by PBC, providing a theoretical basis for further clinical and experimental studies.
文章引用:邱渝, 黄祎, 罗华丽. 代谢功能障碍相关脂肪性肝病合并原发性胆汁性胆管炎的中西医临床研究进展[J]. 临床医学进展, 2025, 15(12): 2549-2555. https://doi.org/10.12677/acm.2025.15123687

参考文献

[1] 耿晓萱, 卢秉久, 郑佳连. 泽明红山方改善大鼠代谢相关脂肪性肝病合并脂肪酸代谢异常的机制研究[J]. 中西医结合肝病杂志, 2025, 35(5): 564-570.
[2] 马狄. ELMO1在原发性胆汁性胆管炎中调控巨噬细胞迁移的机制研究[D]: [硕士学位论文]. 昆明: 昆明医科大学, 2024.
[3] 袁洋, 卜平, 孔桂美, 等. 112例非酒精性脂肪肝证候病机的研究[J]. 中西医结合肝病杂志, 2007(1): 40-42.
[4] 韩诗雨, 田静, 韩煦, 等. 葛根素调控氧化应激与炎症反应改善小鼠脂肪性肝病[J]. 中国中西医结合杂志, 1-8.
[5] 谭钦文, 杜沅沁, 黄鸿娜, 等. 肠道微生态/胆汁酸代谢/FXR途径在NAFLD发展进程中的作用机制[J]. 中西医结合肝病杂志, 2023, 33(5): 467-470.
[6] 马狄, 邰文琳. 巨噬细胞在原发性胆汁性胆管炎发病中的作用机制及影响[J]. 临床肝胆病杂志, 2024, 40(1): 157-160.
[7] 郅果果, 穆杰, 邵冰杰, 等. 脂毒性在非酒精性脂肪性肝炎中的作用机制[J]. 临床肝胆病杂志, 2023, 39(7): 1681-1686.
[8] 张欣媛, 张诺琪, 于国慧, 等. 脂肪因子Chemerin与肝纤维化发生发展的关系[J]. 临床肝胆病杂志, 2025, 41(1): 164-169.
[9] 周铖, 张佳铭, 郭礼, 等. 基于口-肠-肝轴理论探讨原发性肝癌的新型治疗策略[J]. 临床肝胆病杂志, 2020, 36(7): 1646-1649.
[10] 张梦茹, 江若楠, 熊舒华, 等. 从调控昼夜节律稳态角度探讨中药抗肝纤维化潜在作用机制[J]. 中国中药杂志, 2025, 50(16): 4407-4414.
[11] 李茜, 杨洋俊, 孙易, 等. 运动促进肝脏健康: 表观遗传视域下非酒精性脂肪肝病的转归[J]. 中国体育科技, 2024, 60(2): 28-36.
[12] 徐翠瑜, 张明香. 基于肝脾相关理论探讨胆汁酸代谢异常对代谢相关脂肪性肝病的影响[J]. 实用中医内科杂志, 2024, 38(1): 49-52.
[13] 李若瑜, 苗宇船, 苏赵威, 等. 基于1H-NMR技术寻找非酒精性脂肪肝肝郁脾虚证的差异代谢标志物[J]. 中国中医基础医学杂志, 2018, 24(3): 334-336+357.
[14] 李晓东, 肖明中, 卢晨霞, 等. 基于态靶辨治探讨代谢相关脂肪性肝病诊治策略[J]. 中西医结合肝病杂志, 2021, 31(12): 1062-1065.
[15] 李璐, 梁永林, 安冬, 等. 基于“阳中求阴”理论研究左归丸对肾阴虚证能量代谢的影响[J]. 中医药信息, 2021, 38(3): 35-39.